Pasquale Ambrosino1, Roberta Lupoli1, Paolo Tarantino1, Alessandro Di Minno1, Luciano Tarantino2, Matteo Nicola Dario Di Minno3. 1. Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy. 2. Department of Surgery, Interventional Hepatology Unit, Andrea Tortora Hospital, Pagani, Italy. 3. Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy; Unit of Cell and Molecular Biology in Cardiovascular Diseases, Centro Cardiologico Monzino, IRCCS, Milan, Italy. Electronic address: dario.diminno@hotmail.it.
Abstract
BACKGROUND: Anti-phospholipid antibodies positivity is associated with several clinical conditions, including infectious diseases. AIMS: We performed a meta-analysis evaluating the association of hepatitis B and C with anti-phospholipid antibody positivity and with anti-phospholipid antibody-related thrombotic complications. METHODS: Studies evaluating the association of viral hepatitis with anti-cardiolipin, anti-β2 glycoprotein-I and lupus anticoagulant antibodies and anti-phospholipid antibody-related thrombotic events were systematically searched. RESULTS: 20 studies (2319 cases, 1901 controls) were included. The analyses showed that viral hepatitis is associated with the presence of anti-cardiolipin and anti-β2 glycoprotein-I antibodies. The association with anticardiolipin antibodies was confirmed in both hepatitis B (OR 11.22, 95% CI: 6.68-18.84) and hepatitis C (OR 11.26, 95% CI: 6.82-18.59). Similarly, compared to controls, anti-β2 glycoprotein-I antibodies were found more frequently in hepatitis B (OR 14.07, 95% CI: 3.06-64.66) and hepatitis C (OR 5.64, 95% CI: 1.69-18.77). Moreover, 11 studies (257 cases, 1079 controls) showed a higher prevalence of venous and/or arterial thrombosis in patients with hepatitis and anti-cardiolipin antibody positivity compared hepatitis alone (OR 3.29, 95% CI: 1.79-6.07). This result was consistently confirmed in hepatitis C (OR 3.64, 95% CI: 1.78-7.46) but not in hepatitis B. CONCLUSIONS: Viral hepatitis is significantly associated with anti-phospholipid antibody positivity and with anti-phospholipid antibody-related thrombotic complications.
BACKGROUND: Anti-phospholipid antibodies positivity is associated with several clinical conditions, including infectious diseases. AIMS: We performed a meta-analysis evaluating the association of hepatitis B and C with anti-phospholipid antibody positivity and with anti-phospholipid antibody-related thrombotic complications. METHODS: Studies evaluating the association of viral hepatitis with anti-cardiolipin, anti-β2 glycoprotein-I and lupus anticoagulant antibodies and anti-phospholipid antibody-related thrombotic events were systematically searched. RESULTS: 20 studies (2319 cases, 1901 controls) were included. The analyses showed that viral hepatitis is associated with the presence of anti-cardiolipin and anti-β2 glycoprotein-I antibodies. The association with anticardiolipin antibodies was confirmed in both hepatitis B (OR 11.22, 95% CI: 6.68-18.84) and hepatitis C (OR 11.26, 95% CI: 6.82-18.59). Similarly, compared to controls, anti-β2 glycoprotein-I antibodies were found more frequently in hepatitis B (OR 14.07, 95% CI: 3.06-64.66) and hepatitis C (OR 5.64, 95% CI: 1.69-18.77). Moreover, 11 studies (257 cases, 1079 controls) showed a higher prevalence of venous and/or arterial thrombosis in patients with hepatitis and anti-cardiolipin antibody positivity compared hepatitis alone (OR 3.29, 95% CI: 1.79-6.07). This result was consistently confirmed in hepatitis C (OR 3.64, 95% CI: 1.78-7.46) but not in hepatitis B. CONCLUSIONS:Viral hepatitis is significantly associated with anti-phospholipid antibody positivity and with anti-phospholipid antibody-related thrombotic complications.
Authors: Pasquale Ambrosino; Roberta Lupoli; Salvatore Iervolino; Alberto De Felice; Nicola Pappone; Antonio Storino; Matteo Nicola Dario Di Minno Journal: Intern Emerg Med Date: 2017-06-07 Impact factor: 3.397
Authors: Helena Migalovich Sheikhet; Jose Villacorta Hidalgo; Paul Fisch; Alexandra Balbir-Gurman; Yolanda Braun-Moscovici; Ilan Bank Journal: Front Immunol Date: 2018-04-13 Impact factor: 7.561